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Vascular calcification is common in patients with advanced
chronic kidney disease and is associated with poorer
outcomes. Although the pathophysiology is not completely
understood, it is clear that it is a multifactorial process
involving altered mineral metabolism, as well as changes in
systemic and local factors that can promote or inhibit
vascular calcification, and all of these are potential
therapeutic targets. Current therapy is closely linked to
strategies for preventing disordered bone and mineral
metabolism in advanced kidney disease and involves
lowering the circulating levels of both phosphate and
calcium. The efficacy of compounds that specifically target
calcification, such as bisphosphonates and thiosulfate, has
been shown in animals but only in small numbers of humans,
and safety remains an issue. Additional therapies, such as
pyrophosphate, vitamin K, and lowering of pH, are supported
by animal studies, but are yet to be investigated clinically. As
the mineral composition of vascular calcifications is the same
as in bone, potential effects on bone must be addressed with
any therapy for vascular calcification.
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OVERVIEW
Vascular calcification in renal failure
Vascular calcification is restricted to arteries and occurs in
two locations, the intima and the media. Although the
endpoint of both is hydroxyapatite formation, the patho-
physiology and clinical significance are different.1 (The term
hydroxyapatite will be used here, even though in vivo it is
primarily carbonate apatite with partial substitutions of other
ions, such as Mg2þ and F.) Intimal (actually neointimal)
calcification is part of the atherosclerotic process and can
occur in any person with atherosclerosis whether or not they
have kidney disease. It occurs in areas devoid of smooth
muscle cells and is associated with lipid, macrophages, and
mast cells.2 Medial calcification occurs in elastin fibers
around smooth muscle cells in the absence of atherosclerosis
or inflammation1,2 and is seen primarily in chronic renal
failure or diabetes. The prevalence of medial calcification
clearly increases with age,3,4 but whether this is a specific
effect of age or is related to underlying diseases is unclear.
The pattern of vascular involvement differs as well.
Neointimal calcification is limited to the large and med-
ium-sized conduit arteries in which atherosclerosis occurs,5
whereas medial calcification occurs in arteries of any size,
including small arteries in which atherosclerosis does not
occur.6–8 A recent autopsy study of chronic kidney disease
(CKD) patients with known coronary artery disease revealed
that most of the calcification was atherosclerotic with very
little medial calcification,9 whereas a study of mammograms
(presented in abstract form) showed that breast arterial
calcification (which is exclusively medial) was present in
close to 70% of women with end-stage renal disease
(ESRD).10 Involvement can extend to arterioles, which is
observed in calcific uremic arteriolopathy (CUA), a particu-
larly virulent form of medial calcification previously known
as calciphylaxis. Although there is debate about whether the
CUA has a pathophysiology distinct from medial calcification
in larger vessels, it will be considered as a form of medial
calcification for the purposes of this review.
Renal failure increases the extent of calcification in
atherosclerotic plaques,11 but the effect on medial calcifica-
tion is probably greater as it rarely occurs in individuals
without renal insufficiency under the age of 60 years. The
histological prevalence of medial calcification in radial
arteries was 45-fold greater in patients with CKD compared
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with those without CKD,7 and the preliminary report of
breast arterial calcification showed a four-fold higher
prevalence in women with ESRD compared with age-
matched women without renal disease.10 Coronary artery
calcification scores are almost three-fold greater in ESRD
patients than in the age and sex-matched general popu-
lation.12 Because the ESRD patients probably have some
medial calcification as well, the increase in intimal calcifi-
cation is probably less. In unselected autopsy cases, the
prevalence of calcified coronary plaques was 52% in 27
patients with renal insufficiency compared with 37% in 30
subjects without CKD.13
Clinical significance
Treatment of vascular calcification in renal failure rests on the
assumption that it is harmful and that a reduction will be
beneficial. The morbidity of atherosclerosis is related to
vascular occlusion, but it is unclear whether this is
exacerbated by plaque calcification. Medial calcification does
not narrow vessels, but is assumed to stiffen them,14
predisposing to heart failure. This is supported by the fact
that heart failure is the cause of death in children with
infantile arterial calcification, a disorder of severe medial
calcification.15 Lack of arterial distensibility may also trans-
mit greater pulse pressures to the distal arterial bed, leading to
arteriolosclerosis with resulting vascular insufficiency and
tissue damage.14 Of course, without a specific treatment, these
hypotheses cannot be confirmed. Despite this, a large body of
indirect data indicates poorer outcomes in patients with
vascular calcification, and recent clinical trials suggest a
benefit with treatment. A number of studies have shown that
arterial calcification14,16 and progression of calcification17
correlate with cardiovascular events or death, and with
hemodynamic parameters, such as pulse wave velocity. A
study of new hemodialysis patients found a decrease in
mortality associated with the reduced progression of coronary
artery calcification (CAC) in patients treated with sevelamer
compared with calcium-containing phosphate binders, sug-
gesting a beneficial effect of treating vascular calcification.18
Another study of prevalent dialysis patients treated with
sevelamer found improved mortality that was not significant
in the entire cohort, but was significant in predetermined
subgroups.19 This mortality effect is unlikely to be explained
by the reduction in low-density lipoprotein cholesterol that
occurs with sevelamer since cholesterol-lowering therapy does
not alter mortality in ESRD patients.20,21 An additional,
clinically important effect of vascular calcification in renal
failure is the unsuitability of arteries for vascular surgery,
including creation of arteriovenous fistulae and renal
transplantation. Lastly, CUA is a severe, life-threatening
condition. Despite the lack of definitive data, it is hard to
envision that vascular calcification is not detrimental.
Measurement of vascular calcification
The evaluation of therapies for vascular calcification is
problematic because of the lack of good methods to quantify it.
The sensitivity of the various imaging modalities that have
been used is unknown and the precision can be poor.
Computed tomography of the aorta or coronary arteries is
commonly used and is the only modality that can yield truly
quantitative results, but different scoring systems can yield
different results. In addition, the progression of vascular
calcification is quite variable and has a very skewed
distribution so that large numbers of patients are required
and statistical analyses are not straightforward. Lastly, none
of the methods can reliably distinguish between athero-
sclerotic and medial calcification and, therefore, measure the
combined changes in two different pathophysiological
processes. Calcification of coronary arteries, the site most
commonly studied, is mostly atherosclerotic in ESRD
patients,9 and any changes detected could be due to
progression or regression of atherosclerosis rather than to
changes in calcification.
Therapeutic strategies
Vascular calcification and its treatment are linked to the
management of the disordered bone and mineral metabolism
that accompanies CKD. However, there are a number of
potential therapies that directly target the calcification
process. In addition to efficacy and overall safety, two impor-
tant issues affect potential therapies for vascular calcification.
First, is the treatment only preventative or can it reverse
calcification? Second, can vascular calcification be treated
without adversely affecting calcification in normal sites, such
as bone and teeth? Although reversal of calcification is a
desirable therapeutic goal, hydroxyapatite is extremely
insoluble and stable under physiological conditions. Vascular
calcifications also contain whitlockite, which is equally
insoluble, and amorphous calcium phosphate, which may
be more soluble.22 However, medial vascular calcification, in
rats treated with calcitriol or warfarin, does regress when
calcitriol is withheld23 or vitamin K is supplemented,24
indicating that there are endogenous mechanisms for the
dissolution of ectopic hydroxyapatite. Whether this occurs in
more longstanding calcification is unknown, but has been
reported in humans,25 suggesting that prevention of
calcification may eventually lead to reversal. Unwanted effects
on bone is an extremely important therapeutic issue as
mineralized vessels and bone are both composed of
hydroxyapatite and the mechanisms of formation may be
similar. Therefore, an understanding of differences between
vascular calcification and bone formation is essential for
targeting therapy specifically to vessels, and effects on bone
must be addressed with any therapy for vascular calcification.
THERAPIES RELATED TO DISORDERED BONE AND MINERAL
METABOLISM
Secondary hyperparathyroidism (sHPT) is a universal con-
sequence of renal failure and is central in the clinical
approach to disordered bone and mineral metabolism.
However, it is unlikely that parathyroid hormone (PTH)
itself causes vascular calcification. Serum levels do not
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correlate positively with vascular calcification in pa-
tients12,16,26 and PTH does not induce calcification in
vascular smooth muscle cells (VSMCs)27 or intact aortas in
culture.28 Although exogenous PTH produces vascular
calcification in parathyroidectomized rats, this is most likely
due an increase in circulating calcium levels.29 Management
of sHPT focuses on minimizing hyperphosphatemia and
hypocalcemia without producing hypercalcemia and overly
suppressing PTH. This is accomplished with oral phosphate
binders, active vitamin D compounds, calcimimetics, and
adjusting the calcium concentration in the dialysate, all of
which could potentially affect vascular calcification. Conse-
quently, a significant amount of research has been directed at
optimizing these therapies to minimize vascular calcification.
Phosphate binders
Phosphate concentrations above physiological serum levels
have been shown to promote vascular calcification in
experimental models in vivo and in vitro. Supraphysiological
concentrations of phosphate are necessary to induce calcifi-
cation in vessels in vitro28,30–32 and the extent of calcification
varies directly with the phosphate concentration.28 Similarly,
vascular calcification in uremic rats or mice requires a high
phosphorus diet with substantial hyperphosphatemia.33,34
Although a higher serum phosphorus level has been
observed in patients with CKD and ESRD who have vascular
calcification,12,16,35–37 a significant correlation has not been
found in many studies.17,26,38,39 Furthermore, atherosclerotic
calcification in the general population and medial vascular
calcification in diabetics clearly occurs in the absence of
hyperphosphatemia.
The effect of reduced phosphate intake on vascular
calcification is confounded by the concomitant calcium load
from calcium-containing phosphate binders. Studies in
VSMC and cultured aortas have shown dramatic increases
in calcification with incremental calcium concentrations in
culture medium.28,40 In cultured rat aortas, calcification was
proportional to the calcium concentration when the
[Ca] [PO4] product was kept constant, and no calcification
was observed in vessels exposed to high phosphate concen-
trations when the calcium concentration was kept low.28 This
effect of calcium is likely to be physicochemical, not only as a
constituent of apatite but also in the initiation (nucleation)
through binding to elastin41 and through formation of
nascent crystals in matrix vesicles.42 It is not surprising that
calcium intake has correlated with vascular calcification in
several studies in ESRD patients.12,16,26
Several prospective studies have shown a markedly
reduced rate of CAC in ESRD patients treated with sevelamer
(a calcium-free phosphate binder) compared with patients
treated with calcium carbonate or calcium acetate. In the
treat-to-goal study of dialysis patients with existing CAC, the
increase in calcification was 0 and 6% at 26 and 52 weeks
with sevelamer compared with 14 and 25% increases with
calcium carbonate or acetate.43 Aortic calcification was also
significantly reduced. Doses were titrated to the serum
phosphorus level, which did not differ between the two
groups at the end of the study. However, the serum calcium
concentration was significantly lower in the sevelamer group.
Similar results were obtained in a subsequent study of
patients enrolled at the initiation of dialysis.44 A recent study
suggests that this beneficial effect extends to predialysis
patients, with yearly increases in CAC of 48, 39, and 9% for
patients on low phosphorus diet alone, with calcium
carbonate or with sevelamer, respectively.45 In all of these
studies, sevelamer (but not calcium-containing binders)
produced a significant decrease in the serum calcium
concentration and this is presumably the explanation for
the lower rates of vascular calcification. PTH levels and
vitamin D usage were greater in the sevelamer-treated
patients, but these would not be expected to contribute to
a reduction in calcification. Although sevelamer also lowers
low-density lipoprotein levels, a reduction in atherosclerosis
is an unlikely explanation for the reduction in vascular
calcification, as low-density lipoprotein-reduction therapy
has not been successful at reducing coronary artery disease in
ESRD.20,21
Two studies have shown no benefit of sevelamer over
calcium-based phosphate binders.46,47 A high dialysate
calcium concentration was used in many patients in one
study and two-thirds of the sevelamer-treated patients
received calcitriol compared with one-third of the patients
treated with calcium acetate.46 It is not surprising that it is
the only study not to show a decrease in the serum calcium
level with sevelamer. The other study compared sevelamer
with calcium acetate and atorvastatin (as control for the low-
density lipoprotein reduction with sevelamer), but there was
a very high drop-out rate in both treatment groups.47 A very
small study presented in abstract form suggests that
lanthanum carbonate can also prevent CAC,48 but this will
require confirmation in a larger study. Magnesium carbonate
may be another safe and effective calcium-free phosphate
binder49 and it could have additional beneficial effects as
magnesium inhibits hydroxyapatite formation at physiologi-
cal concentrations.50
Active vitamin D compounds
These compounds, which are widely used to treat sHPT in
ESRD and pre-ESRD, are well known to induce medial
vascular calcification in uremic animals. Vascular calcification
is barely observed in rats with subtotal (5/6) nephrectomy fed
a high-phosphate diet unless calcitriol is administered,51,52
and is greatly accelerated by calcitriol in the adenine-feeding
model of renal failure in rats.53 Recent studies in the latter
model, presented in abstract form, showed that doses of
calcitriol required to suppress sHPT increased vascular
calcification.54 Paricalcitol, an analog of calcitriol with a
relatively lower calcemic effect, appears to produce much less
vascular calcification.51 The mechanism by which active
vitamin D affects vascular calcification is unclear. Vascular
smooth muscle has vitamin D receptors and induction of
calcification and calcification-related genes has been observed
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in cultured smooth muscle cells exposed to calcitriol.55
However, this does not occur when intact vessels are treated
in vitro with calcitriol.28 These genes are upregulated in
aortas after prolonged treatment with calcitriol,51 but not
with acute treatment in a recent report in abstract form,54
suggesting an indirect effect.
Data from a mouse model of atherosclerosis and uremia
indicate a biphasic effect of calcitriol, whereby very low doses
inhibit calcification and higher doses promote calcification.56
This could explain the discrepancy between observational
studies showing a survival benefit of calcitriol and analogs in
ESRD, and studies showing promotion of vascular calcifica-
tion in animals. The protective effect of the lower doses may
be due to suppression of sHPT, but the authors have recently
presented evidence in abstract form of effects on smooth
muscle differentiation.57 However, the mouse model is
primarily one of atherosclerotic calcification and the findings
may not apply to medial calcification. The effect of vitamin D
on vascular calcification has not been studied in humans, but
intake does not correlate with vascular calcification in cross-
sectional studies.12,17,58
Other therapies for sHPT
Calcimimetics are the newest therapy for sHPT and reduce
vascular calcification in uremic rats.23,53,59 Again, data are
lacking in humans, but a recently completed study presented
only in abstract form showed a beneficial effect of cinacalcet
on coronary artery and aortic calcification.60 The former was
significant by the volume scoring method, but not the
Agatston scoring method, whereas the latter did not quite
reach significance (Agatston scoring method). Lastly, para-
thyroidectomy prevents vascular calcification in uremic rats59
and subtotal parathyroidectomy can arrest the progression of
CAC in dialysis patients.61 This latter finding was confirmed
in a recent study presented in abstract form.62 It is important
to note that the parathyroidectomized patients had substan-
tially lower serum calcium levels than the nonsurgical
patients, whereas PTH and phosphate levels were unchanged
and the intake of calcitriol and calcium was substantially
higher. Although the number of patients is small, it is hard to
ascribe the effect on vascular calcification to any factor
besides calcium levels.
The role of calcium
A common thread that ties treatment of sHPT to vascular
calcification may be the effect on circulating calcium
concentrations. Although it has been proposed that the link
between these therapies and vascular calcification may relate
to induction of low-turnover bone disease and inability to
buffer calcium loads, severe vascular calcification is also
observed in the high-turnover bone disease associated with
sHPT. Calcium can drive the initial steps in hydroxyapatite
formation63 and small changes in calcium concentration have
profound effects on calcification of aortas in culture.28
Accordingly, calcium-free phosphate binders, calcimimetics,
and parathyroidectomy, which decrease circulating calcium
levels, arrest or prevent vascular calcification, whereas active
vitamin D and calcium-containing phosphate binders, which
increases calcium levels, promote calcification. This suggests
that, in the presence of hyperphosphatemia, circulating
calcium levels should be maintained at the low end of the
normal range and perhaps even below the normal range.
POTENTIAL THERAPIES THAT DIRECTLY TARGET VASCULAR
CALCIFICATION
Pyrophosphate and bisphosphonates
Pyrophosphate (PPi) is a potent inhibitor of calcium
crystallization that circulates at concentrations sufficient to
prevent hydroxyapatite formation in vitro,64–66 and thus
serves as an endogenous inhibitor of calcification. In
particular, production of PPi by smooth muscle may be an
important defense against medial vascular calcification. Rat
aortas do not calcify in culture unless the PPi is removed31
and humans lacking ectonucleotide pyrophosphorylase
(Enpp1), the enzyme that synthesizes extracellular PPi,
develop severe medial arterial calcification at an early
age.67–69 Mice lacking this enzyme or that have a defect in
PPi transport also develop vascular calcification.70 Plasma
levels of PPi may be reduced in hemodialysis patients71 and
correlate inversely with vascular calcification in patients with
ESRD and advanced CKD.72 Alkaline phosphatase, which
hydrolyzes PPi, is upregulated in uremic aortas could
contribute to vascular deficiency of PPi.
Studies over four decades ago showed that PPi inhibits
medial arterial calcification in vitamin D-toxic rats.73
However, rapid hydrolysis of PPi in vivo limited this therapy
and prompted the development of nonhydrolyzable analogs,
such as bisphosphonates that were subsequently shown to
inhibit vascular calcification in the same model, but at much
lower doses.66 More recently, bisphosphonates have been
shown to prevent aortic calcification in uremic rats33,74,75 but
at doses much higher than those used clinically to treat
osteoporosis. In humans, bisphosphonates provide life-
saving therapy for vascular calcification in Enpp1 defi-
ciency,15 but have not shown any effect on coronary artery or
aortic calcification in the general population.76,77 Studies in
CKD and ESRD patients are limited to small studies that
suggest a beneficial effect of etidronate,78–81 but not
alendronate82 on vascular calcification and case reports of
successful treatment of CUA with etidronate or pamidro-
nate,83,84 but larger clinical trials are underway. The fact that
the doses of bisphosphonates necessary to inhibit vascular
calcification in uremic rats also inhibit bone formation33 is
not surprising based on their mechanism of action and raises
serious concerns about their clinical use. Indeed, the positive
results with etidronate and negative results with alendronate
are consistent with the relative potencies in inhibiting bone
formation.85 Larger clinical studies are underway, but are
likely to show no effect based on the type of bisphosphonate
and dosage. An additional concern is that bisphosphonates
are cleared by the kidneys and will accumulate in CKD and
ESRD. Because of potential effects on bone formation and
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accumulation in renal failure, bisphosphonates should be
used with extreme caution for the treatment of uremic
vascular calcification.86
A recent study presented only in abstract form showed
that PPi inhibits vascular calcification in uremic rats without
any adverse effects on bone.87 The differential effects of PPi
and bisphosphonates on bone formation can be explained by
the high level of tissue-nonspecific alkaline phosphatase
(TNAP) in bone, which serves to remove PPi and allow bone
formation at physiological PPi concentrations.70 This is the
basis for the skeletal abnormalities in hypophosphatasia,
which is due to TNAP deficiency. However, TNAP would
not protect bone from the nonhydrolyzable bisphosphonates.
Its selectivity for vascular calcification and the fact that it
does not accumulate in renal failure make PPi a promising
therapy.
Thiosulfate
The use of thiosulfate to treat vascular calcification stems
from reports that it prevents nephrolithiasis in humans.88 A
subsequent study showed that it reduced tumoral calcifica-
tions in renal failure89 and this was followed almost two
decades later by several reports of successful treatment of
CUA with thiosulfate.90,91 However, many of these patients
received other therapies and there have been no randomized
or controlled studies, so the efficacy of thiosulfate is
uncertain. Recently, thiosulfate was shown to inhibit medial
vascular calcification in uremic rats92 and a confirmatory
study has been presented in abstract form.93 In a preliminary
report in abstract form, thiosulfate slowed the progression of
CAC in a very small cohort of dialysis patients,94 and
additional clinical trials are underway. Thiosulfate therapy
does not alter circulating calcium or phosphorus levels88,90,92
and the therapeutic mechanism remains unknown. The
finding that thiosulfate also prevents nephrolithiasis in rats95
and appears to do the same in humans88 points to a direct
effect on calcium crystallization. Despite statements to the
contrary, thiosulfate does not chelate calcium ions though it
does interact with calcium to form ion pairs.96 This
interaction is too weak to have any significant effect on
calcium-dependent reactions at clinically relevant concentra-
tions, including the formation of hydroxyapatite (WC O’Neill
and KA Hardcastle, unpublished data). A disconcerting
finding in rats was a decrease in bone strength,92 raising
the possibility that calcification is also inhibited in bone.
Although thiosulfate has been used to treat nephrolithiasis in
humans for periods of several years without apparent adverse
effects,88 these patients did not have renal failure and
potential effects on bone were not examined.
Vitamin K
Vitamin K is the common name for phylloquinone (vitamin
K1) and several menaquinones (vitamin K2) and serves as a
cofactor for modifying glutamate into g-carboxylated
glutamate (Gla) residues in certain proteins, includ-
ing an important inhibitor of vascular calcification, matrix
gla protein (MGP). Deletion of MGP causes massive aortic
calcification and death in mice.97 Vascular calcification is also
observed in humans lacking MGP, but is much less
extensive.98 Warfarin, which blocks vitamin K-dependent
g-carboxylation of MGP, promotes vascular calcification in
aortas in vitro99 and in rats in vivo,100 which is prevented by
dietary vitamin K.24 Warfarin has been associated with
valvular calcification101–103 and CUA104 (in abstract form
only) in humans, but in the largest study to date, warfarin use
was not associated with increased CAC.105 The relationship
between vitamin K intake and vascular calcification is
unclear. Menaquinone intake was strongly and inversely
correlated with aortic calcification in one study,106 whereas
no correlation was found between dietary vitamin K1 intake
and CAC in another study.107 The disparate results with
vitamin K1 and vitamin K2 are surprising, as vitamin K1 may
be transformed into menaquinone in vivo.
The role of vitamin K deficiency in vascular calcification is
difficult to determine because the assessment of vitamin K
status is challenging and appropriate dosing is unclear.
A recent comprehensive study of 174 patients with CKD stage
3–5 found a high prevalence of subclinical vitamin K
deficiency manifest as an increased fraction of circulating
under-carboxylated osteocalcin in 60% of patients or elevated
levels of undercarboxylated prothrombin in 97% of pa-
tients.108 It is of note that the vitamin K1 (phylloquinone)
levels were reduced only in 6% of patients, suggesting that
vitamin K1 levels may not be sensitive for detection of
subclinical deficiency or that the biochemical abnormalities
are not due to vitamin K deficiency. Higher prevalences of
subclinical vitamin K deficiency and lower levels of
phylloquinone have also been reported in hemodialysis109
and peritoneal dialysis patients.110 Other studies have
reported normal phylloquinone levels in ESRD patients,111
indicating the importance of biochemical markers of vitamin
K deficiency rather than plasma phylloquinone levels. As the
optimum levels of these markers is unclear, the point at
which supplementation should be given and the appropriate
dose are unknown. A daily intake of 1mg of phylloquinone
was needed in young adults to maximize carboxylation of
osteocalcin,112 but the equivalent dose for MGP is unknown.
To date, there are no data to indicate whether the treatment
of apparent vitamin K deficiency in CKD or ESRD is
beneficial or carries any risk.
Acidosis
There is experimental evidence that acidosis may reduce
vascular calcification. In uremic rats fed a high phosphorus
diet and treated with calcitriol, aortic calcification was
prevented by metabolic acidosis that was induced by dietary
ammonium chloride.113 An alkaline pH augments calcifica-
tion of rat aortas in culture28 and even transient increases in
pH equivalent to those occurring during hemodialysis
significantly increased calcification. This raises the possibility
that the practice of alkaline loading during hemodialysis may
contribute to vascular calcification.
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Other potential therapies
Bone morphogenic protein-7 reduces vascular calcification in
a mouse model of atherosclerosis and CKD.114 This is
primarily because of a reduction in the serum phosphate
concentration, although there may be some direct effect on
VSMCs.115 MGP appears to be an important endogenous
inhbibitor of vascular calcification, but its extreme insolubi-
lity precludes it as a therapeutic agent. Although deficiency of
the circulating protein fetuin in mice does not cause vascular
calcification, it does promote calcification in uremia and a
high phosphate diet.116 Its correlation with vascular calcifica-
tion in clinical studies has been variable and its use as a
therapy in animal models has not been reported. Osteopon-
tin is a potent inhibitor of hydroxyapatite formation117 that
inhibits calcification of VSMCs in culture.118 No in vivo
studies have been reported, but osteopontin can inhibit
calcification of other tissues when implanted in osteopontin-
deficient mice.119,120 Other actions of osteopontin that
promote inflammation121 and cancer metastasis122 probably
preclude it as a therapy for vascular calcification. Additional,
but as yet unexplored strategies against vascular calcification
include altering smooth muscle phenotype to reduce its
osteogenic potential, and targeting osteoclastic cells to the
sites of calcification.
CONCLUSIONS
Vascular calcification is common in advanced CKD and likely
contributes to cardiovascular events and death. However,
there are few controlled studies on which to base therapeutic
decisions, and these studies do not distinguish between
medial and intimal calcification, which may show different
responses to therapies. The current state of knowledge
indicates that treatment should be preventative and based
on reducing hyperphosphatemia and minimizing serum
calcium concentrations. Other therapies should be consid-
ered experimental and used with extreme caution pending an
evaluation of simultaneous effects on bone metabolism, as
well as other safety issues. A better understanding of the
biology and chemistry of vascular calcification should lead to
more specific therapies in the future.
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